{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/supporting-evidence/corticosteroids/","result":{"pageContext":{"chapter":{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids","depth":2,"htmlHeader":"<!-- begin field 2779360d-2031-43d9-81f1-5428ae142f8c --><h2>Evidence supporting the use of corticosteroids for an acute attack of gout</h2><!-- end field 2779360d-2031-43d9-81f1-5428ae142f8c -->","summary":null,"htmlStringContent":"<!-- begin item fd5035c8-359f-4aca-94c2-ffe36b1db7f1 --><!-- end item fd5035c8-359f-4aca-94c2-ffe36b1db7f1 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[{"id":"d4985e9d-dc21-5c79-8212-d80b46c04f3d","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids","depth":3,"htmlHeader":"<!-- begin field 1d5c5cf5-2555-4c03-8ebe-c4b97a0104d9 --><h3>Oral corticosteroids</h3><!-- end field 1d5c5cf5-2555-4c03-8ebe-c4b97a0104d9 -->","summary":null,"htmlStringContent":"<!-- begin item b098af46-3036-4d78-b9da-0b611a970906 --><!-- begin field f9593b4f-355b-4af2-9922-43f5ebab13f8 --><ul><li>More trial data are needed to establish whether the use of oral corticosteroids improves symptoms in people with acute gout.</li><li>A randomized controlled trial (RCT) of 90 adults with a clinical diagnosis of gout were allocated (within 3 days of onset of symptoms) to receive oral prednisolone (30 mg for 5 days) or indometacin (50 mg for 5 days) with additional agents. There was no difference in pain scores between the groups, but less adverse effects were seen with prednisolone than indometacin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Man et al, 2007</a>]. A subsequent Cochrane systematic review identified the same study and found no further trials that compared an oral corticosteroid with a nonsteroidal anti-inflammatory drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Janssens et al, 2008</a>].</li><li>A prospective case series compared intravenous methylprednisolone with oral prednisone for treating people with acute gout who had contraindications to the use of nonsteroidal anti-inflammatory drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Groff et al, 1990</a>]:<ul><li>Complete resolution of symptoms occurred within 7 days for 11/13 people, and within 10 days for the remaining two people.</li><li>In the nine people who had fewer than six affected joints, doses of corticosteroid ranged from 20 mg/day to 50 mg/day and were tapered over 4–20 days.</li><li>No rebound attacks occurred when the steroids were stopped.</li></ul></li><li>Different dosing regimens have not been tested in clinical trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li></ul><!-- end field f9593b4f-355b-4af2-9922-43f5ebab13f8 --><!-- end item b098af46-3036-4d78-b9da-0b611a970906 -->","subChapters":[]},{"id":"cdfb8815-e93a-5155-9398-0d6c35c3851c","slug":"intramuscular-corticosteroids","fullItemName":"Intramuscular corticosteroids","depth":3,"htmlHeader":"<!-- begin field e734b4c7-0c1c-42c8-830b-3708b03cc919 --><h3>Intramuscular corticosteroids</h3><!-- end field e734b4c7-0c1c-42c8-830b-3708b03cc919 -->","summary":null,"htmlStringContent":"<!-- begin item e4e1b451-7224-4cfc-9512-bceb4bc39d06 --><!-- begin field ae112574-9e6c-4638-9e4e-728ed4681adf --><ul><li>A review found one non-randomized clinical trial of treatments for acute gout that compared an intramuscular corticosteroid with a nonsteroidal anti-inflammatory drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger et al, 2006b</a>].<ul><li>Oral indometacin 50 mg three times a day was compared with intramuscular triamcinolone acetate 50 mg in a clinical trial of 27 people presenting within 5 days of an attack of gouty arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Alloway et al, 1993</a>].</li><li>People with contraindications to treatment with indometacin received triamcinolone acetonide.</li><li>The mean time to resolution of symptoms was indometacin 8 days; triamcinolone acetate 7 days.</li><li>No adverse effects or episodes of rebound gout occurred with the triamcinolone acetonide therapy.</li></ul></li><li>A subsequent Cochrane systematic review identified the same study and found no further trials that compared an intramuscular corticosteroid with a nonsteroidal anti-inflammatory drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Janssens et al, 2008</a>].</li></ul><!-- end field ae112574-9e6c-4638-9e4e-728ed4681adf --><!-- end item e4e1b451-7224-4cfc-9512-bceb4bc39d06 -->","subChapters":[]},{"id":"7ac70b71-cc6f-58d2-be41-47eca5552dfc","slug":"intra-articular-corticosteroids","fullItemName":"Intra-articular corticosteroids","depth":3,"htmlHeader":"<!-- begin field 0fbc96ce-4fae-47a9-9a19-e03c15db71a3 --><h3>Intra-articular corticosteroids</h3><!-- end field 0fbc96ce-4fae-47a9-9a19-e03c15db71a3 -->","summary":null,"htmlStringContent":"<!-- begin item bc8c8be6-3fd3-42d8-b4e4-5df4c63a130a --><!-- begin field 623ee249-e873-4ae8-aba8-ee261ed76f96 --><ul><li>There are no controlled trials of intra-articular corticosteroids for acute attacks of gout [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Underwood, 2006b</a>].</li><li>The use of intra-articular steroids in acute gouty arthritis is supported by expert opinion, based on clinical experience reported as case series [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Gray et al, 1981</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Fernandez et al, 1999</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Nuki, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li></ul><!-- end field 623ee249-e873-4ae8-aba8-ee261ed76f96 --><!-- end item bc8c8be6-3fd3-42d8-b4e4-5df4c63a130a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}